Evidence map›Paper›PMID 29914886›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2018

Blocking TIR Domain Interactions in TLR9 Signaling.

Artur Javmen, Henryk Szmacinski, Joseph R Lakowicz, Vladimir Y Toshchakov

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Macrophage variants in laboratory research: most are well done, but some are RAW.Frontiers in cellular and infection microbiology · 2024
    Review
  3. Review
  4. TLR5-Derived, TIR-Interacting Decoy Peptides to Inhibit TLR Signaling.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Below the surface: The inner lives of TLR4 and TLR9.Journal of leukocyte biology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Artur JavmenDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201; and.
Henryk SzmacinskiCenter for Fluorescence Spectroscopy, Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201.
Joseph R LakowiczCenter for Fluorescence Spectroscopy, Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201.
Vladimir Y ToshchakovDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201; and vtoshchakov@som.umaryland.edu.ORCID 0000-0002-7942-2294
University of Maryland, Baltimore · US

Funding

Deciphering the architecture of TLR signaling complexesR01AI082299 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI TOSHCHAKOV, VLADIMIR Y. · 2010 to 2020
$3.8M
Coupled Emission Microscopy for the BiosciencesR01GM125976 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI LAKOWICZ, JOSEPH R. · 2018 to 2021
$1.8M
Fluorescence Lifetime Imaging Microscopy (FLIM)S10RR026370 · NCRR · UNIVERSITY OF MARYLAND BALTIMORE · PI LAKOWICZ, JOSEPH R. · 2010 to 2010
$474k
Multi-User Time-Resolved Fluorescence SpectrometerS10OD019975 · OD · UNIVERSITY OF MARYLAND BALTIMORE · PI LAKOWICZ, JOSEPH R. · 2015 to 2015
$243k
NCRR NIH HHS S10 RR026370NIAID NIH HHS R01 AI082299NIGMS NIH HHS R01 GM125976NIH HHS S10 OD019975
6 · The paper itself

Abstract

Interaction of TLR9 with ligands activates NF-κB, leading to proinflammatory cytokine production. Excessive TLR activation is a pathogenic factor for inflammatory diseases. This study has examined cell-permeating decoy peptides (CPDPs) derived from the TLR9 Toll/IL-1R resistance (TIR) domain. CPDP 9R34, which included AB loop, β-strand B, and N-terminal BB loop residues, inhibited TLR9 signaling most potently. CPDPs derived from α-helices C, D, and E (i.e., 9R6, 9R9, and 9R11) also inhibited TLR9-induced cytokines but were less potent than 9R34. 9R34 did not inhibit TLR2/1, TLR4, or TLR7 signaling. The N-terminal deletion modification of 9R34, 9R34-ΔN, inhibited TLR9 as potently as the full length 9R34. Binding of 9R34-ΔN to TIR domains was studied using cell-based Förster resonance energy transfer/fluorescence lifetime imaging approach. Cy3-labeled 9R34-ΔN dose-dependently decreased fluorescence lifetime of TLR9 TIR-Cerulean (Cer) fusion protein. Cy3-9R34-ΔN also bound TIRAP TIR, albeit with a lesser affinity, but not MyD88 TIR, whereas CPDP from the opposite TIR surface, 9R11, bound both adapters and TLR9. i.p. administration of 9R34-ΔN suppressed oligonucleotide-induced systemic cytokines and lethality in mice. This study identifies a potent, TLR9-specific CPDP that targets both receptor dimerization and adapter recruitment. Location of TIR segments that represent inhibitory CPDPs suggests that TIR domains of TLRs and TLR adapters interact through structurally homologous surfaces within primary receptor complex, leading to formation of a double-stranded, filamentous structure. In the presence of TIRAP and MyD88, primary complex can elongate bidirectionally, from two opposite ends, whereas in TIRAP-deficient cells, elongation is unidirectional, only through the αE side.

Indexed as

AnimalsCell Line, TumorCytokinesFemaleHeLa CellsHumansMiceMice, Inbred C57BLMyeloid Differentiation Factor 88PeptidesProtein DomainsSignal TransductionToll-Like Receptor 9CytokinesMyeloid Differentiation Factor 88PeptidesTlr9 protein, mouseToll-Like Receptor 9

Identifiers

PMID29914886
PMCPMC6057823
OpenAlexW2809598090

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.